Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

AC Immune SA (ACIU)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.1600-0.1300 (-3.95%)
At close: 04:00PM EDT
3.1600 0.00 (0.00%)
After hours: 04:49PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Previous Close3.2900
Open3.2700
Bid3.1500 x 1300
Ask3.1800 x 800
Day's Range2.9600 - 3.2700
52 Week Range2.0600 - 8.1400
Volume88,906
Avg. Volume57,925
Market Cap263.587M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateNov 07, 2022 - Nov 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.53
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ACIU

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • AC Immune SA
    Daily Spotlight: VIX Back to 30Fear has returned to the equity market, as inflation readings have failed to cool dramatically, the Federal Reserve remains on a long-term course toward higher rates, U.S. mid-term elections approach, Vladimir Putin threatens the use of nuclear weapons in Eastern Europe, and the global economy reels toward recession. The VIX Volatility Index is a key gauge of investor sentiment and has been elevated above 20 for most of the past two years. Last Friday, after a 486-point drop in the Dow Jones Industrial Average, the VIX closed at 29.92 after touching 32 earlier in the day. A little more than a month ago, the VIX was below 20, and seemingly headed lower as the U.S. consumer economy appeared to be in good shape. How can the market turn so quickly? Investors are always looking ahead, and the latest data (the CPI two weeks ago, the Fed's 75-basis-point hike last week) point toward near-term challenges for the economy, companies, and corporate earnings. New data will be out this week (the Fed's favorite inflation gauge, the PCE indices) and corporate earnings reports will start to flow in mid-October. We expect volatility to remain high, yet the pullback in stock prices unearths some attractive valuations. Buy low and sell high. We think investors should continue to focus on well-managed companies with clear growth objectives and clean balance sheets.
    Rating
    Fair Value
    Economic Moat
    5 days agoArgus Research
View more
  • GlobeNewswire

    AC Immune Partner LMI Progresses Tau PET Tracer PI-2620 into Late-stage Development in Alzheimer’s Disease

    AC Immune’s Tau PET tracer moves closer to becoming a next generation diagnostic for Alzheimer’s Disease (AD)AC Immune to receive a milestone payment from LMI for progress into late-stage product development LAUSANNE, Switzerland, Sept. 26, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that its partner, Life Molecular Imaging (LMI), is moving PI-2620, the Tau positron-

  • GlobeNewswire

    AC Immune Receives a Grant from The Michael J. Fox Foundation for Continued Development of Parkinson’s Disease Diagnostic Imaging Agent

    Previously reported clinical proof-of-concept data on ACI-12589 showed the PET tracer generating the first live images of alpha-synuclein in the human brainNew grant funding will pave the way for enhanced clinical studiesTotal funding from The Michael J. Fox Foundation for AC Immune’s alpha-synuclein PET tracer program is now up to USD 3.7 million LAUSANNE, Switzerland, Sept. 01, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision

  • GlobeNewswire

    AC Immune KOL Webinar on the Potential Benefits of Vaccines for Alzheimer’s and Parkinson’s Diseases

    Vaccines can provide safe, long-lasting immunity, and logistical advantages compared to other treatment modalitiesIntegrating its precision medicine approach, AC Immune is advancing three clinical-stage vaccines targeting Tau, Abeta and α-synucleinPrecisely targeted active immunotherapy may enable prevention of pathological pathways before the occurrence of irreversible neuronal damage LAUSANNE, Switzerland, Aug. 24, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (Nasdaq: ACIU), a clinical-stage biopharm

Advertisement
Advertisement